Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137082 · ClinicalTrials.gov registry record · Phase 1
Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)
A Phase 1 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03137082 is a Phase 1 study that has completed, run by Stony Brook University. The registered enrollment target is 32 participants.
The verdict
NCT03137082, a Phase 1 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Guanfacine may preferentially reduce craving and improve cognitive control in women with Alcohol Use Disorder (AUD), compared to men. As these behaviors are related to relapse, the objectives of this study are to conduct a 10-week out-patient clinical trial to examine the effects of Guanfacine Extended Release (XR; 3mgs) versus placebo on drinking measures in women with AUD.
Interventions
- DRUG Guanfacine XR 3mgs/daily
- DRUG Placebo (for guanfacine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-07-12 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03137082
The ClinicalTrials.gov registry entry for NCT03137082 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Guanfacine XR 3mgs/daily is the first listed.
NCT03137082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03137082 about?
NCT03137082 is a clinical study titled "Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)". Guanfacine may preferentially reduce craving and improve cognitive control in women with Alcohol Use Disorder (AUD), compared to men. As these behaviors are related to relapse, the objectives of this study are to conduct a 10-week out-patient clinical trial to examine the effects of Guanfacine Exten...
What is the current status of trial NCT03137082?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-07-12. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03137082?
The interventions under investigation include: Guanfacine XR 3mgs/daily (DRUG), Placebo (for guanfacine) (DRUG).
Who is sponsoring clinical trial NCT03137082?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.